All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub spoke to Nicholas J. Short, MD Anderson Cancer Center, Houston, US. We asked, Is chemo-free ponatinib, venetoclax, and dexamethasone safe/effective in patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) ALL?
Is chemo-free ponatinib, venetoclax, and dexamethasone safe/effective in patients with R/R Ph+ ALL?
In this video, Short discusses data from phase I of a phase I/II study on the combination of ponatinib, venetoclax, and dexamethasone in patients with relapsed/refractory Ph+ ALL, where outcomes are traditionally very poor.
Could ponatinib + blinatumomab substitute chemo + allo-HSCT as frontline therapy for Ph+ acute lymphoblastic leukemia?
During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Could...
Too much of a good thing? An in vitro study with dual Src/ABL kinase inhibitor and blinatumomab suggests some combination treatments for Ph+ ALL may not work well together
The most common cytogenic abnormality in adult patients with acute...
Subscribe to get the best content related to ALL delivered to your inbox